Cargando…
The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448498/ https://www.ncbi.nlm.nih.gov/pubmed/36067790 http://dx.doi.org/10.1098/rsif.2022.0477 |
_version_ | 1784784075710529536 |
---|---|
author | Kraay, A. N. M. Gallagher, M. E. Ge, Y. Han, P. Baker, J. M. Koelle, K. Handel, A. Lopman, B. A. |
author_facet | Kraay, A. N. M. Gallagher, M. E. Ge, Y. Han, P. Baker, J. M. Koelle, K. Handel, A. Lopman, B. A. |
author_sort | Kraay, A. N. M. |
collection | PubMed |
description | Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts. |
format | Online Article Text |
id | pubmed-9448498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94484982022-09-14 The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 Kraay, A. N. M. Gallagher, M. E. Ge, Y. Han, P. Baker, J. M. Koelle, K. Handel, A. Lopman, B. A. J R Soc Interface Life Sciences–Engineering interface Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts. The Royal Society 2022-09-07 /pmc/articles/PMC9448498/ /pubmed/36067790 http://dx.doi.org/10.1098/rsif.2022.0477 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited. |
spellingShingle | Life Sciences–Engineering interface Kraay, A. N. M. Gallagher, M. E. Ge, Y. Han, P. Baker, J. M. Koelle, K. Handel, A. Lopman, B. A. The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title | The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title_full | The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title_fullStr | The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title_full_unstemmed | The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title_short | The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 |
title_sort | role of booster vaccination and ongoing viral evolution in seasonal circulation of sars-cov-2 |
topic | Life Sciences–Engineering interface |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448498/ https://www.ncbi.nlm.nih.gov/pubmed/36067790 http://dx.doi.org/10.1098/rsif.2022.0477 |
work_keys_str_mv | AT kraayanm theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT gallagherme theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT gey theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT hanp theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT bakerjm theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT koellek theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT handela theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT lopmanba theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT kraayanm roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT gallagherme roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT gey roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT hanp roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT bakerjm roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT koellek roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT handela roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 AT lopmanba roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2 |